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 ABSTRACT 
Background: Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome is characterized by 
congenital aplasia of the uterus and the upper part of the vagina in women showing normal 
development of secondary sexual characteristics and a normal 46, XX karyotype. The 
uterovaginal aplasia is either isolated (type I) or more frequently associated with other 
malformations (type II or Müllerian Renal Cervico-thoracic Somite (MURCS) association), 
some of which belong to the malformation spectrum of DiGeorge phenotype (DGS). Its 
etiology remains poorly understood. Thus the phenotypic manifestations of MRKH and DGS 
overlap suggesting a possible genetic link. This would potentially have clinical consequences. 
Methods: We searched DiGeorge critical chromosomal regions for chromosomal anomalies 
in a cohort of 57 subjects with uterovaginal aplasia (55 women and 2 aborted fetuses). For 
this candidate locus approach, we used a multiplex ligation-dependent probe amplification 
(MLPA) assay based on a kit designed for investigation of the chromosomal regions known to 
be involved in DGS. 
The deletions detected were validated by Duplex PCR/liquid chromatography (DP/LC) and/or 
array-CGH analysis.  
Results: We found deletions in four probands within the four chromosomal loci 4q34-qter, 
8p23.1, 10p14 and 22q11.2 implicated in almost all cases of DGS syndrome. 
Conclusion: Uterovaginal aplasia appears to be an additional feature of the broad spectrum of 
the DGS phenotype. The DiGeorge critical chromosomal regions may be candidate loci for a 
subset of MRKH syndrome (MURCS association) individuals. However, the genes mapping 
at the sites of these deletions involved in uterovaginal anomalies remain to be determined. 
These findings have consequences for clinical investigations, the care of patients and their 
relatives, and genetic counseling. 
 BACKGROUND 
Congenital aplasia of the uterus and the upper two thirds of the vagina is diagnosed as Mayer-
Rokitansky-Küster-Hauser (MRKH) syndrome in 90% of affected women presenting with 
primary amenorrhea and otherwise normal secondary sexual characteristics, normal ovaries 
and a normal karyotype (46, XX) [1]. The incidence of MRKH syndrome has been estimated 
to be 1 in 4500 female births [2-4]. The uterovaginal aplasia can be isolated (type I; OMIM 
277000) but it is more frequently associated with other malformations (type II; OMIM 
6601076). Type II is also referred to as the MURCS (Müllerian Renal Cervico-thoracic 
Somite anomalies) association. The most common associated malformations involve the 
upper urinary tract affecting about 40% of patients [5] and the cervicothoracic spine affecting 
about 30 to 40% of patients [5-7]. Renal malformations include unilateral agenesis, ectopia of 
one or both kidneys, horseshoe kidney, hydronephrosis [7], and even bilateral renal agenesis 
(Potter sequence) [8]. Rachidial malformations most commonly encountered are scoliosis, 
isolated vertebral anomalies (asymmetric, fused or wedged vertebrae), Klippel-Feil 
association or Sprengel deformity [7, 9]. Less frequent associated anomalies include hearing 
defects in about 10 to 25% of patients [10-11]. Cardiac malformations, such as tetralogy of 
Fallot [12], atrial septal defect [13] or pulmonary valvular stenosis [14] are found in rare 
cases, as rare facial asymmetry [15-17] and digital anomalies, such as brachymesophalangy, 
ectrodactyly or duplicated thumb [18-20]. Type II MRKH or the MURCS association may be 
attributed to alterations in the blastema giving rise to the cervicothoracic somites and the 
pronephric ducts, the ultimate spatial relationships of which are already determined by the end 
of the fourth week of fetal development [21]. 
MRKH syndrome was initially considered to be sporadic. The involvement of non-genetic or 
environmental factors was suggested but rejected. The description of an increasing and 
significant number of familial cases confirmed the involvement of a genetic component. The 
 syndrome appears to be transmitted as an autosomal dominant trait with incomplete 
penetrance and variable expressivity [2, 22-24]. Observations are consistent with a polygenic 
or multifactorial cause involving either mutations in one or several major developmental 
genes or limited chromosomal imbalances. However, the etiology of MRKH syndrome 
remains poorly understood (see [1] for review). At the present time, only a SHOX duplication 
has been described associated with type I MRKH syndrome in some cases [25].  
In respect to type II MRKH or MURCS association, the lack of clear genetic or chromosomal 
evidence led us to consider the wider spectrum of uterovaginal aplasia-associated 
malformations as a starting point for genetic investigations. We compared MRKH syndrome 
with other syndromes displaying phenotypic features overlapping with those of MRKH 
syndrome. Several of the anomalies found in the MRKH syndrome are also within the clinical 
spectrum of the 22q11.2 deletion syndrome, also referred to as DiGeorge syndrome (DGS 
syndrome; OMIM 188400) and velocardiofacial syndrome (VCF syndrome; OMIM 192430). 
Indeed, this phenotype involves congenital heart defects, such as tetralogy of Fallot, 
interrupted aortic arch, ventricular septal defect or persistent troncus arteriosus, dysmorphic 
facial features, cleft palate, hearing loss, thymic hypoplasia, hypoparathyroïdism, and 
developmental and behavioral problems [26-28]. Other less common manifestations include 
renal (horseshoe, hydronephrosis), vertebral (butterfly vertebrae, hemivertebrae, abnormalities 
of the cervical spine, scoliosis, Sprengel deformity) and extremity anomalies (polydactyly, 
syndactyly, club-foot) [28-30]. Ninety% of cases of DGS and 70% of cases of VCF syndrome 
are caused by a 1.5 to 3.0 Mb hemizygous deletion of chromosome 22q11.2 [31]. More 
precisely, the strictly DiGeorge syndrome appears to be associated with only TBX1 deletion or 
mutations [32]. However, DGS-like phenotypes have also been reported in patients with 
deletions of chromosome 4q34.2-qter [33-34], 8p23-pter [34-36], 10p14-p15 [34, 37-41], 
17p13 [42] or 18q21 [43], chromosomes 4, 8 and 10 being the most frequently chromosomes 
 described associated with DGS-like phenotype. Some studies have described MRKH 
syndrome features associated with 22q11.2 deletions [8, 44-47] and we showed a 4q34-qter 
deletion in one case of MRKH syndrome [48].  
Here, we report a search in a cohort of 57 patients affected by the MRKH syndrome for 
deletions in the chromosomal regions most frequently associated with the DGS or the DGS-
like phenotypes. 
PATIENTS AND METHODS 
Patients  
We studied 55 women who presented utero-vaginal aplasia diagnosed by clinical examination 
and transabdominal ultrasonography and/or magnetic resonance imaging (MRI) or celioscopy. 
All patients had a normal 46, XX karyotype. The patients underwent a check-up to search for 
associated malformations including renal ultrasonography, spine radiography and 
echocardiography or audiogram, if required. Twenty (36.4%) presented isolated uterovaginal 
aplasia (MRKH type I). The other women (63.6%) variously displayed kidney defects, 
vertebral and other skeletal malformations (including Klippel-Feil and Sprengel anomalies, 
digital anomalies such as clinodactyly, brachydactyly and syndactyly), cardiac anomalies and 
hearing impairment. Two aborted fetuses with various abnormalities including uterovaginal 
aplasia were also analyzed.  
All the subjects were enrolled through a French national multicentric research program, called 
PRAM (Programme de Recherche sur les Aplasies Müllériennes), which is registered in the 
Orphanet database (http://orphanet.infobiogen.fr). This study was approved by the local 
institutional review board, the “Comité de Protection des Personnes” (Project # 05/16-543), 
and is registered with the French Ministry of Health (DGS # 2005/030). Here, we only report 
the clinical features of the four subjects in whom we detected a deletion. 
Case 1 
 This patient presented with primary amenorrhea, leading to a diagnosis of congenital absence 
of the upper vagina and uterus, with normal bilateral adnexa, as confirmed by celioscopy. 
Thelarche and pubarche were normal. The patient had no visceral malformations (the heart 
and kidneys, in particular, were normal, as assessed by ultrasound examinations) or hearing 
impairment. No skeletal abnormalities were observed. This patient was about 165 cm tall. Her 
schooling was standard and she was the only daughter of non consanguineous parents who 
suffered one miscarriage. Her father had no relevant medical background. Her mother was 
152 cm tall and was 58 years old at the time of the study. At birth, the patient’s mother had 
bilateral club feet. An atrial septal defect (ostium secundum type) was subsequently detected, 
requiring surgical correction at the age of 23. Bilateral serous carcinoma of the Fallopian 
tubes was diagnosed four years ago. The patient’s mother had no renal defects or skeletal 
abnormalities. No mental impairment or other visceral malformations were reported in this 
family. 
Case 2 
This 19-year-old female patient was referred for the evaluation of primary amenorrhea. 
Thelarche and adrenarche had occurred at 13 years of age. Congenital uterovaginal aplasia 
with symmetric muscular buds, bilaterally normal ovaries and Fallopian tubes were 
demonstrated by celioscopy. Screening for anomalies commonly associated with MRKH 
syndrome revealed unilateral kidney agenesis but no other defects. In particular, this patient 
displayed no deafness or skeletal, heart, limb and facial malformations. She also had no 
psychiatric disorders. This patient had two sisters and two brothers, none of whom have any 
malformations. Her parents were phenotypically normal but were unavailable for further 
investigation. There was no family history of recurrent abortion or consanguinity.  
Case 3 
 Case 3 was a fetus from a medically terminated pregnancy at 18 weeks of gestation following 
the ultrasonographic discovery of a bilateral renal agenesis. Fetopathological examination 
confirmed the absence of kidneys associated with uterovaginal aplasia. No other skeletal or 
heart malformation was observed. We later established that the father and the two sisters also 
displayed unilateral renal agenesis, without associated heart or skeletal malformation. Fetal 
ultrasound of the two sisters did not reveal any uterine malformation but no genital 
examination was performed (the children were too young). Case 3 had a normal 46, XX 
karyotype. The mother had no relevant medical history. One of the first-degree female 
cousins of the father presented unilateral renal agenesis also associated with ipsilateral half-
uterus.  
Case 4 
This case was a female fetus obtained following medically termination of a pregnancy at 23.5 
weeks of gestation due to bilateral renal agenesis. Fetopathological examination showed, in 
addition to the bilateral renal agenesis, uterovaginal aplasia, type B interrupted aortic arch, 
and thymic hypoplasia. Neither parent had morphological anomalies. This case has been 
preliminarily reported in a study of 49 fetuses with three or more significant anomalies of 
unknown etiology, in which a battery of CGH methods were applied to detect chromosomal 
imbalances [49]. 
Healthy control subjects 
About 15% of genes in the OMIM morbid map overlap CNVs (Redon, 2006). CNVs can 
cause Mendelian or sporadic traits, or be associated with complex diseases. Probands can 
inherit a disease-associated rearrangement from unaffected parents, which underscores the 
variable penetrance of some diseases resulting from dosage effects (Redon, 2006). However, 
CNVs can also be benign polymorphism variants. To confirm that the deletions observed in 
the present cases were not non-pathogenic genomic copy number variations (CNV), a cohort 
 of 100 healthy normal subjects (50 men and 50 women) was tested. All volunteers were 
informed about the study and signed a consent form approved by the local Ethical Committee.  
Methods 
Genomic DNA was extracted from whole blood of patients or from fetal tissues, whole blood 
of parents and healthy control subjects using the QIAamp DNA Kit (http://www.qiagen.com) 
according to the manufacturer’s protocol. 
MLPA 
Multiplex ligation-dependent probe amplification (MLPA) was performed with samples from 
our cohort of 57 MRKH syndrome patients, the parents if possible and 100 healthy control 
subjects. Two independent experiments were carried out each on 100ng of genomic DNA. We 
used the SALSA MLPA kit P023-DiGeorge (MRC-Holland, Amsterdam, Netherlands) 
according to the manufacturer’s instructions. This kit allows semi-quantitative analysis of 39 
genomic sequences located on 4q (six targets), 7p15 (one target), 8p (five targets), 10p (five 
targets), 17p13 (four targets), 18q21 (two targets), 22q11 (ten targets) and 22q13 (one target); 
most of these loci are involved in DGS or DGS-like phenotypes. Amplification products were 
analyzed by capillary electrophoresis using an ABI 3100 Genetic Analyzer (Applied 
Biosystems). ABI result files were normalized using the GeneMarker Software (Softgenetics) 
and an in-house Excel spreadsheet. The results are represented as histograms.  
Duplex PCR/liquid chromatography (DP/LC) 
The chromosomal breakpoints in cases 2 and 3 were confirmed and mapped more precisely 
using multiplex PCR/liquid chromatography in a duplex assay according to a standard 
protocol [50]. Briefly, duplex PCR was used, associating unlabeled primers for an 
endogenous control gene, HMBS, and for the region showing imbalance in the tested patient. 
This enables simultaneous amplification of the two targets under semi-quantitative conditions. 
Primers were designed using Primer Premier Software (Premier Biosoft International, Palo 
 Alto, CA, USA). Navigator™ Software (Transgenomic, Omaha, NE, USA) was used for data 
analysis and the HMBS peak was used for normalization; relative peak intensities for each 
amplicon directly reflected genomic copy number. 
Array-CGH 
Oligonucleotide array-CGH analysis was performed using the Agilent Human Genome CGH 
microarray 44K (Agilent Technologies, Santa Clara, CA, USA) as described in version 4.0 of 
the protocol provided by Agilent (Agilent Oligonucleotide Array-Based CGH for Genomic 
DNA Analysis). This platform is constituted of 44,290 60-mer oligonucleotide probes for 
mapped genes or unique DNA sequences with an average spatial resolution of 35Kb. Patient 
and same gender reference genomic DNA (gDNA) were digested, labeled with Cy5™-dUTP 
and Cy3™-dUTP using the Agilent Genomic DNA Labeling Kit PLUS and cohybridized to 
Agilent 4 x 44k arrays. After washes, hybridized slides were scanned on the Agilent scanner 
G2565BA. Images were analyzed with Agilent Feature Extraction Software version 9.1 
(CGH-v4_91 protocol). Data were imported into Agilent CGH analytics software version 
3.4.27 (statistical algorithm: z-score, sensitivity threshold: 2.5, moving average window: 5 
points) for a graphical overview and analysis. 
RESULTS 
The 57 patients and 100 healthy control subjects were tested by MLPA with the P023 kit. 
None of the control subjects showed variation in the copy number for any of the markers used 
in this kit. The analysis disclosed a deletion at different chromosomal regions in each of four 
patients (Figure 1): deletion of three probes (FLJ10474 corresponding to ODZ3 gene, CASP3, 
KLKB1) at 4q34-qter in case 1; one probe (MSRA gene) at 8p23 in case 2; one probe 
(MGC10848 corresponding to ITIH5 gene) at 10p14 in case 3; and seven probes (KIAA1652 
and FLJ14360 corresponding to TXNRD2 and KLHL22 genes, respectively, HIRA, CLDN5, 
PCQAP, SNAP29, LZTR1) at 22q11.2 in case 4. 
 For case 1, testing with the MLPA P023 kit revealed an identical deletion of about 8 Mb at 
4q34-qter in the mother, but no deletion was found in the father. A complementary DP/LC 
analysis, reported previously, corroborated these results [48]. We confirmed and refined this 
former analysis by array-CGH and demonstrated that there were no other chromosomal 
abnormalities in either the proband or her mother, and no abnormality in her father (Figure 2). 
MLPA analysis of case 2 led to detect a single copy of the MSRA gene on chromosome 8p23 
but two copies of the flanking genes, PPP1R3B and GATA4, were found in the same MLPA 
experiment, leading to estimate the maximum size of the deletion to be 2.6 Mb. The 
chromosomal breakpoint was more accurately mapped using DL/PC with amplicons located 
in TNKS, MSRA (used to corroborate MLPA results), UNQ9391, RP1L1, SOX7, PINX genes 
and in the C8orf74 open reading frame: the maximum size of the deletion was then found to 
be 1.2 Mb in between TNKS and UNQ9391 (Figure 3). However, we could not investigate 
either this case by array-CGH (insufficient genomic DNA was available) or her parents 
because we were unable to contact the family again. 
MLPA analysis of case 3 revealed a deletion of 0.9 Mb maximum in the 10p14 region which 
includes the whole ITIH5 gene. DP/LC of the SFMBT2 and ITIH2 genes flanking the ITIH5 
gene mapped this deletion to a maximal size of 230 Kb, including only the ITIH5 gene 
(Figure 4A). In addition, array-CGH analysis showed no deletion of the markers flanking the 
ITIH5 gene or in other parts of the genome (data not shown). Thus, this deletion appears to be 
very small. MLPA, DP/LC and array-CGH analysis identified no deletion in the father, the 
two sisters, the first-degree paternal female cousin who presented unilateral renal agenesis, or 
in the phenotypically normal mother and two paternal aunts. The pedigree of this family is 
shown in Figure 4B. 
MLPA analysis of case 4 confirmed and refined the preliminary results published on this case. 
Deletion of three clustered probes (RP1-157E19, RP1-238C15, and RP11-316L10) at 22q11.2 
 was found by array-CGH and confirmed by QMPSF (Quantitative Multiplex PCR of Short 
Fluorescent fragments) (TBX1 amplicon) [49]. Comparison of the 6.3 Mb deletion initially 
found by array-CGH and that of 5.95 Mb we detected by MLPA indicated that the deletion 
was 5.24 Mb maximum. 
DISCUSSION 
We report four chromosomal deletions located at 4q34-qter, 8p23, 10p14 and 22q11.2, all 
known to be associated with DGS or DGS-like phenotypes, in four independent MRKH 
subjects. 
To differentiate clinically relevant deletions from non pathogenic chromosomal variants, we 
first consulted the Database of Genomic Variants (http://projects.tcag.ca/variation/) to exclude 
copy number variations (CNVs) previously observed in control healthy individuals. CNVs 
within each of the loci investigated in our study were reported to be absent, smaller or very 
rare (<0.5%). To distinguish between potentially pathogenic variants and unidentified benign 
CNVs, we tested 100 DNA samples from healthy volunteers with the same MLPA kit. No 
variation in copy number was observed in these controls for any of the markers used in this 
kit. The size of the deletions found in the described cases and the absence of deletion at these 
loci from all controls, strongly suggest that the four deletions we identified are pathogenic.  
Deletion of 4q34-qter may lead to a phenotype similar to the DiGeorge phenotype [33-34], 
including congenital heart disease (atrial septal defect, ventricular septal defect), cleft palate, 
and learning difficulties. Few cases of 4q34-qter deletion have been reported [33, 51-52] and 
there are only three reports of familial transmission affecting the mother and her sons showing 
features of DiGeorge syndrome [52-54]. The present case 1 is the fourth described case of 
familial transmission of 4q34-qter deletion and the first case associated with MRKH 
syndrome inherited from a mother displaying different clinical features. Several genes are 
included in this deletion: the FAT tumor suppressor 1 (FAT1) gene, which belongs to the 
 cadherin superfamily [55], appears to be a common candidate gene for malformations 
observed in both the daughter and the mother [48]. First, FAT1 has been described as one of 
the five tumor suppressor gene located on the long arm of chromosome 4 [56-59] and was 
evidenced as an anti-proliferative factor of smooth muscle cells [60]. So, it might account for 
the bilateral serous carcinoma of the Fallopian tubes, discovered in case 1's mother when she 
was 54, as previously discussed [48]. Second, the FAT1 gene appears to be also a putative 
candidate gene for a developmental failure of Müllerian differentiation in the embryo. Indeed, 
the protein encoded by this gene has been shown to take an important part to developmental 
processes requiring cell polarization [61], cell-cell interactions [55] and epithelium-
mesenchyme interaction [62] such as tubulogenesis [63]. In particular, it seems to be involved 
in smooth muscle differentiation process [62] and could therefore give an explanation to the 
Müllerian duct differentiation arrest observed in MRKH syndrome. In this hypothesis, 
haploinsufficiency of the FAT1 gene would lead to unequal consequences, probably 
depending on each patient’s genomic background and affecting embryonic or adult tissues. It 
may therefore be helpful for future studies to request further information about internal 
genital anomalies and cancer susceptibility in individuals with 4q deletions. 
Small interstitial deletions within the 8p23.1 region, such as that found in case 2, have been 
associated with severe congenital heart disease, mental retardation, microcephaly, and a 
characteristic behavioral phenotype, all these features being included in DGS-like phenotype 
[35-36]. The GATA4 gene at 8p23.1-pter has been implicated in all such cases with a heart 
defect [36, 64-65] but not in patients without heart defects [36]. The region deleted from our 
patient mapped close to GATA4, but did not include this gene, consistent with the phenotype 
of this patient. Deletion of 8p23.1 has also been shown to be associated with renal anomalies 
(hydronephrosis, horseshoe kidney), vertebral anomalies, and polydactyly [64-67]. All these 
features are included in the associated malformations of type II MRKH (MURCS association) 
 [1]. This suggests that the different clinical features observed in case 2 may be caused by the 
deletion of clustered genes within the commonly deleted region and that the 8p23.1 
chromosomal region corresponding to a DGS-like morbid locus includes at least one gene 
involved in MRKH syndrome. This region contains the peptide methionine sulfoxide 
reductase (MSRA) gene [68], the retina-specific RP1L1 gene [69], MIR 124-1, a micro-RNA 
preferentially expressed in the developing brain [70], the TNKS gene involved in regulating 
telomere length [71], and other genes of unknown function. None of the known genes in this 
region is particularly likely to be involved in MRKH syndrome. Finding redundant deletions 
in a larger cohort of patients would certainly be of great help to map the MRKH-associated 
genomic region on 8p23.1 and identify candidate gene(s). 
Chromosome 10p terminal deletions have also been associated with DiGeorge-like 
phenotypes [39-40, 72]. Studies of patients with 10p deletions have allowed the definition of 
two non-overlapping regions that contribute to this complex phenotype: the DiGeorge critical 
region 2 (DGCR2) [39, 72] located on 10p13-14 associated with heart defects and T-cell 
deficiency; and the HDR region located on 10p14-10pter associated with hypoparathyroïdism, 
sensorineural deafness, and renal defect [73]. This implies that the DGS-like phenotype 
associated with 10p deletion can be considered as a contiguous gene syndrome [74]. GATA3 
haploinsufficiency is the underlying defect in the HDR syndrome [73] and BRUNOL3 is a 
candidate gene for thymus hypoplasia and possibly for heart defects [75]. Our case 3 is the 
first reported case of 10p14 deletion associated with uterovaginal aplasia. This deletion seems 
to affect only the ITIH5 gene, located in the HDR locus, distal to the GATA3 gene and might 
account for genital abnormalities associated with renal defects. This suggests that the ITIH5 
gene may be involved in a common mechanism of renal and genital tract differentiation and 
that GATA3 haploinsufficiency independently only causes renal defects. 
 Finally, the 22q11.2 deletion is the genetic etiology of about 90% of cases of DiGeorge 
syndrome [31]. Six cases of uterovaginal aplasia have been reported with 22q11.2 deletion. In 
1997, Devriendt et al. described a 19-week female fetus with MRKH syndrome, unilateral 
renal agenesis, and contralateral multicystic renal dysplasia [8]. In 2006, Cheroki et al. 
analyzed five cases of uterovaginal aplasia associated with other malformations by array-
CGH: a 22q11.2 deletion (~4 Mb in size) was detected in a young woman presenting tract 
genital, heart, skeletal and facial anomalies but no renal defect [44]. In the four other cases, 
uterovaginal aplasia was associated with unilateral renal agenesis and other manifestations 
(facial anomalies, mild developmental delay, hypoparathyroïdism, skeletal or heart defect) 
[45-47]. Here, we report an additional case (case 4) of 22q11.2 deletion associated with 
uterovaginal aplasia, thymic hypoplasia, interrupted aortic arch type B, and for the first time, 
bilateral renal agenesis. The smallest common deleted region among the deletions overlapping 
22q11.2 and associated with MRKH type II (MURCS association) is the most frequent ~3 Mb 
22q11.2 deletion associated with DGS [76] (Figure 5). This strongly suggests that the 
MURCS association is an additional component of the 22q11.2 deletion phenotype. However, 
the genes within 22q11.2 deletion involved in both renal and uterovaginal anomalies remain 
to be determined. 
CONCLUSION 
The MRKH syndrome is characterized by congenital uterovaginal aplasia frequently 
associated with extragenital anomalies (MURCS association). These other manifestations, 
such as renal, skeletal and heart malformations are also found in DGS or DGS-like 
phenotypes. Our results show that uterovaginal aplasia can also be associated with deletions 
in known DGS (22q11.2) or DGS-like (4q34-qter, 8p23, and 10p14) loci. These data suggest 
that the MURCS association may be an additional feature of the broad phenotypic spectrum 
of DiGeorge syndrome. In the light of this information, the extent of malformations in cases 
 of either MRKH syndrome or DGS syndrome should be reconsidered. Patients with MRKH 
syndrome, especially MURCS association, should undergo evaluation of chromosomal 
regions responsible of DGS or DGS-like phenotypes. Similarly, patients diagnosed for DGS 
syndrome should be assessed for genital malformations. 
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Figure legends 
Figure 1: MLPA analysis of cases 1 to 4. Gene dosage in cases 1 to 4 assessed by the MLPA 
P023 kit. Histogramms represent allelic dosage of each target gene. Black arrows show 
deletion of (A) FLJ10474 (ODZ3), CASP3 and KLKB1 probes at 4q34-qter in case 1; (B) 
MSRA probe at 8p23 in case 2; (C) MGC10848 (ITIH5) probe at 10p14 in case 3; (D) HIRA, 
CLDN5, KIAA1652 (TXNRD2), FLJ14360 (KLHL22), PCQAP, SNAP29, LZTR1 probes at 
22q11.2 in case 4. 
Figure 2: Array-CGH profile of chromosome 4 in case 1 and her parents. A deletion of  
about 8 Mb was detected in 4q34-qter in case 1 and her mother (black boxes). No deletion 
was found in her father. Log2 ratio values for all probes are plotted as a function of their 
chromosomal position. Solid and dotted lines indicate the log2 ratio thresholds -0.25 (loss) 
and 0.25 (gain), respectively. 
Figure 3: Details of the 8p23 deletion found in case 2. Summary of gene quantification and 
chromosome breakpoint refinement: several genes were tested by MLPA (P023 kit) and 
DP/LC. The combined results show an about 1.2 Mb deletion delimited by TNKS and 
UNQ9391 gene markers and including MSRA. NA: Not Applicable. 
 Figure 4: Details of the 10p14 deletion in case 3. A. Summary of gene quantification and 
chromosome breakpoint refinement: several genes were tested by MLPA (P023 kit) and 
DP/LC. Combination of the results indicates a heterozygous deletion of about 230 Kb 
including the ITIH5 gene. NA: Not Applicable. B. Pedigree of the case 3’s family. The 
proband is indicated with an arrow. Question marks indicate that the phenotype of putative 
genetic carriers is unknown.  
Figure 5: Diagram of 22q11.1-q11.23 chromosomal region. Schematic representation of 
the 22q11.1-q11.23 chromosomal region between 15 and 23 Mb from the telomeric end of the 
short arm. Dark gray box represents the ~3Mb most common 22q11 deletion associated with 
DGS syndrome; white boxes represent the maximum distance between undeleted markers in 
this current study (case 4) and the previously reported MRKH cases. Light gray box shows 
the smallest 22q11.2 deletion common to known MRKH syndrome patients. 
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Figure 1
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Figure 5
